85%Confidence
0Views
FDASource
2026-04-10Date
Summary
Teva faces a Class II recall for Octreotide Acetate due to sterility concerns from a contract manufacturer in Greece, indicating potential supply disruptions and reputational damage for this injectable product. This highlights ongoing quality control risks in Teva's outsourced manufacturing network, which may lead to increased regulatory scrutiny and financial impacts.
Actionable: Monitor Teva's supply chain for further disruptions and assess alternative suppliers for affected products.
AI Confidence: 85%
Data Points
firmTeva Pharmaceuticals USA, Inc
classificationClass II
statusOngoing
distributionNationwide in the USA
productOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 20 mg, Single-dose 8 mL vial, Rx only, Manufactured in Greece BY: Pharmat
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now